This study will evaluate the safety and effectiveness of an investigational new animal anti-inflammatory drug in dogs experiencing acute onset pancreatitis (AOP) symptoms. Acute onset pancreatitis in dogs is caused by sudden inflammation of the pancreas. Symptoms may include loss of appetite, vomiting, abdominal pain, lethargy, dehydration, and in severe cases, organ failure.
The current standard for AOP involves supportive care and management of complications by parenteral fluid therapy, anti-nausea medications, pain management, nutritional support, and antibiotics (if appropriate). In contrast, the novel drug directly inhibits the inflammatory response of the pancreas, which may protect against the more severe effects of AOP, such as organ failure.
What to Expect
- This is a 10 day study.
- The patient will need to come in for 2 visits with their owner, one of these visits will include a hospital stay (resulting in a 5-day total commitment).
- In addition, the owner will be asked to document anything unusual over the course of the 10 day study.
- Placebo Group: Patients will be split evenly into 2 groups by random selection. All participants in the study will receive, at least, the current standard of care treatment for pancreatitis.
- 50% of patients will receive treatment with the investigational drug,
- The other 50% will receive standard-of-care treatment with no investigational drug.
Dogs presenting with mild symptoms of AOP:
- Vomiting or lack of appetite, painful stomach or hunchback posture, tiredness, dehydration or diarrhea.
- Is at least 6 months of age or older.
- Does not currently experience severe diseases other than AOP.
- Massachusetts Veterinary Referral Hospital, Woburn, MA
- Veterinary Specialty Hospital – Sorrento Valley, San Diego, CA
Enroll or request more information below